Mammary Cell News 12.01 January 16, 2020 | |
| |
TOP STORYARID1A inactivation in cells and in patients led to resistance to estrogen-receptor degraders by facilitating a switch from estrogen-receptor-dependent luminal cells to estrogen-receptor-independent basal-like cells. [Nat Genet] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists showed that a proapoptotic secretory phenotype was induced by activation of cGAS/STING in cancer cells that were hit by antimitotic treatment, accumulated micronuclei and maintained mitochondrial integrity despite intrinsic apoptotic pressure. [Nat Commun] Full Article Researchers demonstrated that breast epithelial cells acquired malignant properties when exposed to medium conditioned by macrophages derived from human healthy donors. These effects were mediated by the breast cancer oncogene IKKε and its downstream target, the serine biosynthesis pathway. [EMBO Mol Med] Full Article | Graphical Abstract Breast cancer cells were injected in the carotid artery of mice to preferentially induce metastasis in the brain, and samples were collected at different time points to follow metastasis development. [Mol Oncol] Abstract | Full Article miRNAs as Radio-Response Biomarkers for Breast Cancer Stem Cells Exposition of breast cancer cells to radiation doses affected their phenotype, functional characteristics, pluripotency gene expression, and in vivo tumorigenic capacity. [Mol Oncol] Abstract | Full Article APOBEC3B Expression in Breast Cancer Cell Lines and Tumors Depends on the Estrogen Receptor Status The authors measured the expression of APOBEC3A and APOBEC3B genes in two breast cancer cell lines treated with estradiol, cisplatin, or their combination. [Carcinogenesis] Full Article Liquid chromatography-tandem mass spectrometry was employed to analyze enriched membrane N-glycomes from five breast cancer cell lines and one brain cancer cell line. [J Proteome Res] Abstract | Graphical Abstract Scientists report that exosomes derived from antisense oligonucleotide (ASO-1537S)-treated MDA-MB-231 breast cancer cells inhibited tumorigenesis of recipient cells, in contrast to exosomes derived from control-ASO-treated cells which, in contrast, enhanced these properties. [Sci Rep] Full Article BAD Sensitizes Breast Cancer Cells to Docetaxel with Increased Mitotic Arrest and Necroptosis Researchers showed that docetaxel therapy preferentially reduced growth of Bcl-2-associated death promoter (BAD)-expressing xenograft tumors. They explored the cellular mechanism whereby BAD sensitized cells to docetaxel. [Sci Rep] Full Article SAG Expression Associates with COPB2-Related Signaling and a Poorer Prognosis in Breast Cancer Investigators revealed that SAG gene expression was upregulated in breast cancer cells and that SAG overexpression was associated with significant poorer survival in breast cancer, especially the luminal A subtype. [Aging (Albany NY)] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSBreast Cancer Stem Cell Antigens as Targets for Immunotherapy The authors summarize the controversial nature of breast cancer stem cells, discuss why they represent good candidates for cancer immunotherapy, and review the cancer stem cell antigens that have been used as targets for cancer stem cell immunotargeting. [Semin Immunol] Abstract | Graphical Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSQuantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. announced a collaboration to evaluate trilaciclib in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. [G1 Therapeutics, Inc.] Press Release Zymeworks Inc. announced the initiation of a Phase II trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance®, an oral CDK4/6 inhibitor. [Zymeworks, Inc.] Press Release | |
| |
POLICY NEWSFlorida Cracks Down on Foreign Government Involvement in Research Florida is launching a statewide investigation into US research exploitation after four University of Florida faculty members and six employees of Moffitt Cancer Center in Tampa failed to disclose ties to foreign programs, reports the Tampa Bay Times. [The Scientist] Editorial FDA and NIH Let Clinical Trial Sponsors Keep Results Secret, Investigation Shows For 20 years, the US government has urged companies, universities, and other institutions that conduct clinical trials to record their results in a federal database, so doctors and patients can see whether new treatments are safe and effective. [STAT News] Editorial
| |
EVENTSNEW 2nd Epigenetics Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – DNA Nanotechonology in Cancer (University of Duisburg-Essen) NEW Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute) Investigator Position – Cancer Cell Biology (Winthrop P. Rockefeller Cancer Institute) Postdoctoral Research Fellow – Breast Cancer Research (University of South Carolina) Leader – Breast Cancer Program (Fred Hutchinson Cancer Research Center) Postdoctoral Position – Fibroblasts in Breast Cancer (Institut Curie) Postdoctoral Fellowship – Molecular Mechanisms in Cancers (Cleveland Clinic) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|